Anton Rx Report

Ambulatory Infusion Centers (AICs) are once again gaining traction….. but not for the first time. AICs have actually been around for a very long time.

Most insurance programs still place provider administered medications under the medical benefit requiring that the meds be billed to the payer in the traditional claims

Hospital / Health System Owned Specialty Pharmacies (HHOSPs) have been saying that they are better qualified than independent SPs because they are integrated, essentially bolted

Last week the FDA approved a new ORAL therapy, Welireg (belzutifan) from Merck, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for

If you have made healthcare a career then you are likely to be familiar with NCQA. They’ve been around since the early 1990s measuring and

Now here’s something ya don’t see every day….. a leading accreditation body cutting a deal to offer a discount on specialty pharmacy accreditation. Yes, URAC

Last week the FDA approved a new, INFUSED enzyme replacement therapy, Nexviazyme (avalglucosidase alfa-ngpt) from Genzyme, indicated to treat patients 1 year of age and

It was way back in March of 2015 when the first biosimilar was approved. There was much consternation over the impact that biosimilars would have

The FDA recently approved a new therapy, Saphnelo (anifrolumab-fnia) from AstraZeneca, as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard

The FDA recently approved a new ORAL therapy, Bylvay (odevixibat) from Albireo Pharma, with an indication for treating pruritus in all subtypes of progressive familial